LEO Pharma is a leader in thrombosis with a specific focus on cancer associated thrombosis.
We have worked with healthcare professionals to care for people with thrombosis for over 80 years. We strive to improve
lives with high ethics and holistic support, setting new standards of care.
LEO Pharma headquarters are in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries.
For more information please visit: https://www.leo-pharma.co.uk/Home/Our-focus/Thrombotic-Conditions.aspx
We are here for people at every step, helping to create, improve and prolong life. We deliver personalized treatments for serious diseases and enable people to achieve their dream of becoming parents. We empower the scientific community. Our tools, services and digital platforms make research simpler, more exact, and help to deliver breakthroughs more
quickly. Our solutions accelerate access to health by ensuring tests are accurate and the medicine we take can be trusted. We are the company behind the companies, advancing digital living. Our science sits inside technologies that are changing the way we access, store, process, and display information. Our innovations are unlocking the power and potential of data to open new possibilities to transform life on Earth as we know it.
At Takeda Oncology, we endeavour to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, we are finding innovative ways to improve the treatment of cancer. We know that our mission is not a quick or simple one, but we are up for the task: we aspire to cure cancer.
To learn more, visit us at www.takeda.com/en-gb/
The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in cancer patients undergoing chemotherapy. The system’s concept came when mother of four, Sue Paxman, experienced the trauma of chemotherapy-induced hair loss. As the leading expert and supplier, Paxman’s pioneering system has helped thousands of people worldwide.
B. Braun stands for over 180 years of innovative solutions in healthcare, with a passionate workforce of ambitious people who contribute to the company ethos of protecting and improving the health of people around the world.
Headquartered in Melsungen, Germany, B. Braun is one of the world’s leading providers and manufacturers of high quality product systems and service.
Roche is the world’s largest biotech company and a pioneer in pharmaceuticals and diagnostics, focused on advancing science to improve people’s lives. Roche has created truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system.
Roche has been working to transform cancer care for more than 50 years, bringing the first specifically designed anti-cancer chemotherapy drug to patients in 1962. Roche’s commitment to developing innovative medicines and diagnostics for cancers remains steadfast.
Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives.
Our drug discovery and development efforts were founded in 2002 in Wilmington, Delaware, USA, by a team of research scientists, chemists and biologists working in immunology. Today, we employ approximately 1500 people and have operations in the US, Europe and Japan.
Our unique expertise in medicinal chemistry and biology have enabled us to create a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing pipeline of medicines across two franchises: Oncology and Inflammation & Autoimmunity.
The commitment of our talented team of world-class scientists to continued scientific excellence has enabled us to identify new molecules, decipher new pathways and develop first-in-class and best-in-class medicines.
At Rosemont our mission is to be a rapid developer, reliable manufacturer and global supplier of novel-delivery, patient-focused medicines.
Our ambition has always been to support both patients with swallowing difficulties and the healthcare professionals who care for them. We are highly respected in the industry and have been instrumental in establishing best practice for the care of patients with swallowing difficulties. Rosemont advocate the use of liquid medication over manipulating solid dose medications and we have a range of educational materials designed for healthcare professionals which focuses on key patient groups and their medication management challenges.
At Rosemont we have a portfolio of over 130 oral liquid medicines across a range of therapeutic areas including 70 licensed products. All of our products, both licensed and ‘specials’ are made to the same exacting standards under GMP. Our UK range also includes 9 products licensed for use with PEG/NG tubes. We are always seeking to expand our range of medicines and covert our ‘specials’ to licensed product wherever possible.